Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

Core Viewpoint - Profound Medical Corp. is set to announce its second quarter 2025 financial results on August 14, 2025, and will host a conference call to discuss these results and business developments [1][2]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing customizable, incision-free therapies for the ablation of diseased tissue [3]. Product Offerings - The company is commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven transurethral ultrasound for the treatment of prostate diseases. The TULSA procedure is designed to preserve urinary continence and sexual function while effectively targeting prostate tissue [4]. - TULSA is a single-session, incision-free procedure that operates at temperatures of 55-57°C, with no associated bleeding or hospital stay required, allowing for quick recovery [4]. - Profound is also marketing Sonalleve, a therapeutic platform approved for treating uterine fibroids and palliative pain from bone metastases. It has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments [5].